This SYCP2-augemented HR pathway in cancer cells not only allows them to survival intrinsic DNA damage, but also makes them resistant to the DNA damage induced by DDR-targeted drugs, providing a potential therapeutic target and a biomarker for DDR therapy response in cancers. The gene discussed is SYCP2; the disease is cancer.